Keymed Biosciences (HKSE:02162) NonCurrent Deferred Liabilities: HK$0.0 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02162 Keymed Biosciences Inc HKSE:02162
47 GF Score
Price HK$73.55
GF Value HK$151.02
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Keymed Biosciences NonCurrent Deferred Liabilities?

Keymed Biosciences HKSE:02162 -3.73% 47 NonCurrent Deferred Liabilities is HK$0.0 Mil as of Dec. 2025. GuruFocus rates HKSE:02162 with a GF Score™ of 47/100 and a GF Value™ of HK$151.02 (Possible Value Trap). The stock has 4 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Keymed Biosciences's non-current deferred liabilities for the quarter that ended in Dec. 2025 was HK$0.0 Mil.

Keymed Biosciences NonCurrent Deferred Liabilities Related Terms

Keymed Biosciences NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Keymed Biosciences's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Keymed Biosciences NonCurrent Deferred Liabilities Chart

Keymed Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Keymed Biosciences Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HKSE:02162
47GF Score
Keymed Biosciences Inc HKSE:02162
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of HK$0.0 Mil mean?
Keymed Biosciences (HKSE:02162) has a NonCurrent Deferred Liabilities of HK$0.0 Mil as of Dec. 2025. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Keymed Biosciences and its competitors.
Is Keymed Biosciences' NonCurrent Deferred Liabilities too high?
Keymed Biosciences' current NonCurrent Deferred Liabilities is HK$0.0 Mil. Overall, Keymed Biosciences has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Keymed Biosciences' NonCurrent Deferred Liabilities compare to VRTX and REGN?
Keymed Biosciences' NonCurrent Deferred Liabilities of HK$0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Keymed Biosciences and its competitors. Keymed Biosciences's current NonCurrent Deferred Liabilities is HK$0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Keymed Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Keymed Biosciences (HKSE:02162) is currently considered Possible Value Trap. The stock's GF Value™ is HK$151.02, compared to a current price of HK$73.55 — trading 51.3% below its estimated fair value. The current NonCurrent Deferred Liabilities is HK$0.0 Mil. Keymed Biosciences' overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Keymed Biosciences (HKSE:02162), the current NonCurrent Deferred Liabilities is HK$0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Keymed Biosciences (HKSE:02162) Overvalued in 2026?

Based on GuruFocus' analysis, Keymed Biosciences stock appears to be undervalued. The current stock price of HK$73.55 is trading 51.3% below its estimated GF Value™ of HK$151.02. GuruFocus considers Keymed Biosciences to be Possible Value Trap.

Key valuation signals for HKSE:02162:

  • NonCurrent Deferred Liabilities: HK$0.0 Mil
  • GF Value™: HK$151.02 vs. price of HK$73.55 (51.3% below fair value)
  • GF Score™: 47/100 with 4 warning signs

No single metric tells the full story. See the HKSE:02162 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Keymed Biosciences Business Description

Other Exchanges 64Z:Germany
Address No. 669 Fenghuang Road, Shuangliu District, Chengdu, Sichuan, CHN, 610219
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.
47GF Score

Get the complete analysis for HKSE:02162

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$73.55
Price
HK$151.02
GF Value